セッション

検索結果は5件です。

Is the WHO 2010 classification sufficient to clearly characterize pancreatic neuroendocrine carcinoma?
Hijioka Susumu(Department of Gastroenterology, Aichi Cancer Center Hospital, Japan)
Background:The WHO 2000 classification of pancreatic neuroendocrine tumors(pNET)addressed morphological differentiation as the first criterion;however, the 2010 classification is based on histo...

第100回日本消化器病学会総会Short Oral Presentations(Pancreaticobiliary disorders 2)

Pancreatic Ductal Adenocarcinoma(PDAC):Identification of compounds that inhibit NUPR1 protein function in cell culture
Abian Olga(Aragon Health Science Institute, Spain)
Because pancreatic cancer is often diagnosed at a late stage, surgical removal of the tumor is often difficult, if not impossible. Pancreatic ductal adenocarcinoma, or PDAC, is by far the most common ...

第100回日本消化器病学会総会Short Oral Presentations(Pancreaticobiliary disorders 2)

Loss of runt-related transcription factor 3 induces gemcitabine resistance via increasing the expression of multidrug resistant protein in pancreatic cancer
Horiguchi Shigeru(Department of Gastroenterology & Hepatology, Okayama University Graduate School of Medicine, Japan)
Background and Aim:Runt-related transcription factor 3(RUNX3)is a tumor suppressor gene discovered in gastric cancer. RUNX3 is lost or decreased in various cancer tissues, including pancreatic ...

第100回日本消化器病学会総会Short Oral Presentations(Pancreaticobiliary disorders 2)

Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts
Kanda Mitsuro(Department of Gastroenterological Surgery(Surgery II), Nagoya University Graduate School of Medicine, Japan)
Objective;Pancreatic cysts are commonly detected in patients undergoing pancreatic imaging. Better approaches are needed to characterise these lesions. In this study we evaluated the utility of...

第100回日本消化器病学会総会Short Oral Presentations(Pancreaticobiliary disorders 2)

Investigation of biological characteristics of biliary tract cancers to establish a novel molecular-targeted therapy
Yokoyama Masaaki(Kyorin University, Japan)
<Purpose>
The purpose of this study is to investigate various genes mutations and protein overexpression in biliary tract cancer(BTC), in order to establish most optimal molecular targeted therapy....

第100回日本消化器病学会総会Short Oral Presentations(Pancreaticobiliary disorders 2)